Compare NOVT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | APGE |
|---|---|---|
| Founded | 1968 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 1999 | 2023 |
| Metric | NOVT | APGE |
|---|---|---|
| Price | $141.94 | $134.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $144.00 | $109.67 |
| AVG Volume (30 Days) | 456.9K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $521,290,000.00 | N/A |
| Revenue This Year | $8.61 | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $276.08 | ★ N/A |
| Revenue Growth | ★ 35.49 | N/A |
| 52 Week Low | $98.27 | $34.34 |
| 52 Week High | $171.85 | $134.46 |
| Indicator | NOVT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 79.90 |
| Support Level | $131.26 | $80.52 |
| Resistance Level | $149.42 | N/A |
| Average True Range (ATR) | 6.48 | 0.31 |
| MACD | -0.97 | -1.73 |
| Stochastic Oscillator | 21.72 | 75.00 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.